---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-24-000030"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:45:33.302441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60

## Summary
- Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.
- Non-GAAP diluted EPS $4.08 (-6% YoY); FY2024 Non-GAAP EPS guidance raised to $16.10-$16.60 (~11% growth at midpoint).
- LEQEMBI global in-market sales ~$67M (US $39M); other launches delivered sequential revenue growth.
- Dapirolizumab pegol Phase 3 met primary endpoint in SLE; second Phase 3 study to initiate in 2024.
- Nusinersen higher dose showed statistically significant improvement; global regulatory submissions planned.

## SEC filing metadata
- accession: 0000875045-24-000030
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/0000875045-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504524000030/biib-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-24-000030
- JSON: https://secwatch.observer/filing/0000875045-24-000030.json
- Plain text: https://secwatch.observer/filing/0000875045-24-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.